NCT01786603View on ClinicalTrials.gov

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 21, 2013

Primary Completion Date

July 27, 2016

Study Completion Date

July 27, 2016

Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
DRUG

Rasagiline

Rasagiline 2mg once a day for 12 months.

DRUG

Placebo

Placebo (looks like study drug but has no active ingredients) once a day for 12 months.

Trial Locations (10)

10032

Columbia University, New York

19107

University of Pennsylvania, Philadelphia

63104

St. Louis University, St Louis

66160

University of Kansas Medical Center, Kansas City

68198

University of Nebraska, Omaha

75390

UT Southwestern Medical Center, Dallas

85018

Phoenix Neurological Associates, Phoenix

92868

University of California - Irvine, Irvine

94115

California Pacific Medical Center, San Francisco

97239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Richard Barohn, MD

OTHER

NCT01786603 - Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter